<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601235</url>
  </required_header>
  <id_info>
    <org_study_id>NMDEMS0214NA-III</org_study_id>
    <nct_id>NCT02601235</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pediatric Drugs in Nasal Congestion</brief_title>
  <official_title>Clinical Evaluation of Safety and Efficacy of Pediatric Naridrin in Comparison to Afrin on the Improval of Nasal Congestion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the Naridrin in improving nasal
      congestion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, multicenter clinical study. Maximal experiment duration: 2 days; 2
      visits. Safety and efficacy evaluation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of Nasal Congestion</measure>
    <time_frame>2 days</time_frame>
    <description>Relief of nasal congestion will be measured on a scale of 0 to 3 (0 = without congestion and 3 total congestion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 days</time_frame>
    <description>Safety of the drug will be assessed by observation of adverse events monitored for the type, frequency and intensity during the days of the follow-up.
The evaluation of the heart frequency will also be a safety parameter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Nasal Congestion</condition>
  <arm_group>
    <arm_group_label>Naridrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naridrin: 2 drops in each nostril once daily as prescription</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.05 % Oxymetazoline Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 pumps in each nostril every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naridrin</intervention_name>
    <description>Naridrin® : 2 drops in each nostril once daily as prescription</description>
    <arm_group_label>Naridrin</arm_group_label>
    <other_name>Naphazoline Hydrochloride</other_name>
    <other_name>Mepyramine Maleate</other_name>
    <other_name>Dexpanthenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afrin</intervention_name>
    <description>2 pumps in each nostril every 12 hours.</description>
    <arm_group_label>0.05 % Oxymetazoline Hydrochloride</arm_group_label>
    <other_name>oxymetazoline hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants aged 10-17 years old with clinical symptoms of inflammatory of allergic
             nasal congestion in at least one nostril due to rhinitis or rhinopharyngitis (cold or
             flu);

          -  Signed Consent;

          -  Participants whose mother, father and / or legal guardian is in accordance with all
             study purposes and procedures;

          -  Participants with clinical symptoms of nasal congestion in at least one nostril
             diagnosed through the Glatzel mirror;

          -  Participants with minimal score of 2 points in the 0 to 3 scale (Moderate
             obstruction).

        Exclusion Criteria:

          -  Participation in clinical trial in the year prior to this study;

          -  Total obstruction of one of the nostrils by other etiologies that are not inflammatory
             or allergic;

          -  Infectious bacterial-disease (clinically diagnosed);

          -  Participants treated with antibiotic or possible antibiotic use due to another medical
             condition;

          -  Use of intranasal corticosteroids (7 days prior to the study) or systemic (15 days
             prior to the study), regarding the plasma half-life of the drug;

          -  Use of decongestants or antihistamine (intranasal or systemic) in the 03 days prior to
             the study;

          -  Use of inhaled drugs (except nasal moisturizers such as saline solution) or treatment
             with immunosuppressants in the week before the study;

          -  Participants with septum deviation grade II and III, nasal polyps, severe turbinate
             hypertrophy, adenoid hypertrophy, or other determining factors for nasal obstruction;

          -  History of hyperthyroidism or hypertension;

          -  History of hypersensitivity to the components of the study drugs;

          -  History of transphenoidal hypophysectomy or oronasal surgery with exposure of the
             dura-mater;

          -  Exclusive mouth-breathers patients;

          -  Participants in chronic drug treatment for allergies (eg vaccines for allergy,
             cromolyn);

          -  History of alcohol and / or drug abuse 3 months prior to the study;

          -  Smokers

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  PAny clinical, laboratory that, in the judgment of the investigator, may interfere
             with the safety of research participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa F.B. Oliveira, M.D.</last_name>
    <phone>+ 55 19 3887-9851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neusa Wandalsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasal congestion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Naphazoline</mesh_term>
    <mesh_term>Pyrilamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

